• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
183691 165 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
( ], R. R% S1 {7 R. q0 F% r, d& U; F; ]" `
6 p+ t' e5 R4 X5 U* G
Sub-category:
% A$ ^0 _/ D$ q! [% zMolecular Targets
# l4 M3 q) _; S2 }$ v! h
% M9 @9 ^0 a8 V, k- L$ g/ s3 H  M0 k. i7 b  p* n
Category:; R& a0 U" I/ E4 e+ i9 g7 v( G
Tumor Biology 6 t: P' _/ o) G7 s* N$ D0 U$ o
, V2 k" l) n/ p! e) A0 B+ n

! s% z5 Q& ~" G& aMeeting:
, D2 I  k# ^8 @# Z3 m' ^6 Y2011 ASCO Annual Meeting
# C+ M$ \) j9 d# J8 f! r
; X4 h; @! U7 c6 `
) q0 [+ N" i4 K1 q. ISession Type and Session Title:
0 V2 W$ K% |+ h/ ?! k3 jPoster Discussion Session, Tumor Biology
. l# P2 [! o8 e" H  [2 {# Z6 `' E* c( S* E0 p7 R

$ }2 S; \8 e. o! F3 S. u" _Abstract No:
' P( S6 j  C1 }5 Z7 L10517
/ ?1 o1 r6 _4 r* Z. `- o8 I" a# [" U) A6 ~/ y
* I' S; t) e0 k. d3 f* T# Z# |$ L
Citation:  V. u4 M' A& T$ |
J Clin Oncol 29: 2011 (suppl; abstr 10517)
2 k: J) m4 e! f" V( p# L) w% s& S8 f' p8 U' Z) W# c  `  q0 Y
5 ~6 K7 u5 {* |+ W6 |) ~& @
Author(s):
0 G! p1 H. ~7 P" oJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
& x, n) P1 M. K' m( K7 d. b' j) `! J/ ?0 W% b% T- K1 X

) C% d  s& d0 }! q
/ ?8 ~: y# }2 x; q- t4 hAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 T  P' E+ V2 H9 W$ ]0 J2 g. I7 D' J3 j1 G
Abstract Disclosures9 n# r, c! ~& p2 U4 _' l

- d7 O7 w& s! I0 w" cAbstract:
7 I; a0 {1 }7 b) I$ b: b  f! M; i& q: j" e  b2 f" D1 E) l
0 @) R8 K5 i8 S% g7 D
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
( l2 y( N2 G  W0 [0 K3 t) f
* B" c9 ?4 y& u! b0 q1 m( X5 m : i  C+ Y6 \- ]) }$ W& P+ t
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 . ^6 S" y* D* x5 @% P& e. Y
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

# h) b6 G  |5 k( `% g化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 7 w# q% |4 `/ k3 J' A
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。, \6 b9 I+ }1 s/ E( u4 J& b
ALK一个指标医院要900多 ...

, O# R; a% a. g3 q' E0 F8 R1 T* Z( `平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?5 h" j/ L1 @0 p6 |! c4 n+ A
! I, J5 k# Q5 b. X! g* H' Y0 @
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表